Amyvid (Florbetapir F18) in injectable solution gets approval in the European Union for use in the diagnosis of patients with cognitive impairment Alzheimers disease and other causes.
Amyvid (Florbetapir F18) in injectable solution gets approval in the European Union for use in the diagnosis of patients with cognitive impairment Alzheimer’s disease and other causes. Amyvid is the first and only indicated diagnosis for testing PET agent that allows you to identify the density of the plate beta-amyloid in the brain neuritic. Indianapolis (USA)UU), January 2013.- Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., wholly owned subsidiary of Lilly, have announced that the European Commission has approved Amyvid (Florbetapir F18) solution for perfusion as a radiopharmaceutical indicated diagnosis for PET (positron emission tomography) test that can identify the density of the plate beta-amyloid in the brain of adult patients neuritic with cognitive impairment, which is evaluating a possible diagnosis of Alzheimer’s disease and other causes of cognitive impairment. Amyvid should be used in conjunction with clinica1 evaluation. Amyvid joins the amyloid plaques, one of the characteristic neuropatologicas of the of Alzheimer disease (ad) (2,3,4) and detected using PET imaging of the brain.(1) Amyvid is the first and only diagnostic tool adopted by the European Union showing the presence or absence of density of plaques of beta-amyloid in the brain neuritic ”, says Diane Bakaysa, international head of Amyvid Lilly. Amyvid, along with a clinical evaluation, can be an important aid to doctors who treat patients with cognitive impairment. It is important because it is estimated...
Read More